•Alzheimer's disease is the most common form of cognitive impairment in older adults, accounting for about 70 percent of persons living with dementia.

• The overall AD burden possibly expands to include nearly 55 percent of persons with mild cognitive impairment and nearly 30 percent of cognitively unimpaired people.
• The global cost due to AD is estimated to be nearly 1 trillion USD, and the inflation-adjusted cost may balloon to nearly 2 trillion USD by 2030.
• Among the most important adaptations needed for widespread use of AD-modifying treatments will be the manner of how sufficient clinical workforce personnel and health care infrastructure will be available to provide timely and equitable access to diagnosis, treatment, and care.
• This editorial advocates the necessary next steps to  support appropriate, affordable, widespread use to develop sufficiently accurate blood tests and to  empower primary care clinicians to reduce the percentage of their patients  who need PET scan or lumbar puncture

https://doi.org/10.1002/alz.12533